Brain atrophy: frontal-temporal

Quibim

Quibim's Frontotemporal atrophy quantifies the volumes of the right and left hippocampus, frontal lobes and temporal lobes, to help assess disease diagnosis and progression. The obtained values are framed in a normative database to be compared with healthy subjects of the same age and gender. This suite can be used to aid diagnosis and monitoring of patients with Alzheimer’s disease, mild cognitive impairment and frontotemporal dementia.
Product specifications Information source: Vendor
Last updated: Feb. 11, 2022
General
Product name Brain atrophy: frontal-temporal
Company Quibim
Subspeciality Neuro
Modality MR
Disease targeted Alzheimer's, Frontotemporal dementia, Mild Cognitive Impairment (MCI)
Key-features Absolute and relative volume
Suggested use Without interference of a radiologist: AI-only diagnosis
Data characteristics
Population Patients with neurological degenerative disease
Input MRI T1 GRE 3D T1 Fast Gradient Echo
Input format
Output One-page structured report: 3D brain parcellation render, lobe segmentation, table with volume statistics, normative bars of volume
Output format DICOM Secondary Capture / PDF
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition
Processing time > 10 minutes
Certification
CE
Certified, Class IIa , MDD
FDA
 No or not yet
Market presence
On market since 01-2019
Distribution channels Alma HEALTH PLATFORM
Countries present (clinical, non-research use) 6
Paying clinical customers (institutes) 5+
Research/test users (institutes)
Pricing
Pricing model License
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers